Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

Pfizer was using hospitalization as primary endpoint for their their fusion inhibitor so a signal on that endpoint is great. The concern would be how long it takes to enroll a phase 3 they were planning on 2k and if you limit the study to 75 and up and copd/chf that could take a long time so feasibility issues. Obviously w a 80 percent reduction you wouldn’t need 2k but still that might be a concern for a partner
Nevertheless in the whole very good data IMO